A Study to Evaluate the Efficacy and Safety of Sintilimab in Combination With IBI305 (Anti-VEGF Monoclonal Antibody) Compared to Sorafenib as the First-Line Treatment for Advanced Hepatocellular Carcinoma.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03794440 |
Recruitment Status : Unknown
Verified May 2020 by Innovent Biologics (Suzhou) Co. Ltd..
Recruitment status was: Active, not recruiting
First Posted : January 7, 2019
Last Update Posted : January 22, 2021
|
- Study Details
- Tabular View
- Results Submitted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Hepatocellular Carcinoma | Drug: Sintilimab Drug: IBI305 Drug: Sorafenib | Phase 2 Phase 3 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 595 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | A Randomized, Open-label,Multi-center Study to Evaluate the Efficacy and Safety of the Combination of Sintilimab and IBI305 Compared to Sorafenib in the First-Line Treatment of Patients With Advanced Hepatocellular Carcinoma. (ORIENT-32) |
Actual Study Start Date : | February 11, 2019 |
Estimated Primary Completion Date : | December 2022 |
Estimated Study Completion Date : | December 2022 |
Arm | Intervention/treatment |
---|---|
Experimental: Sintilimab +IBI305 |
Drug: Sintilimab
200mg IV d1, Q3W
Other Name: IBI308 Drug: IBI305 15mg/kg IV d1, Q3W
Other Name: anti-VEGF monoclonal antibody |
Active Comparator: Sorafenib |
Drug: Sorafenib
400mg PO BID |
- Overall survival (OS) [ Time Frame: up to 24 months after randomization ]
- Progression-free survival (PFS) [ Time Frame: up to 24 months after randomization ]Progression-free survival (PFS) in two arms based on RECIST V1.1 by Independent Radiological Review Committee, IRRC.
- PFS [ Time Frame: up to 24 months after randomization ]PFS in two arms based on RECIST V1.1 by investigator.
- Objective response rate (ORR) [ Time Frame: up to 24 months after randomization ]Objective response rate (ORR) in two arms based on RECIST V1.1 by IRRC and investigator .
- Disease control rate (DCR) [ Time Frame: up to 24 months after randomization ]DCR in two arms based on RECIST V1.1 by IRRC and investigator.
- Duration of response (DOR) [ Time Frame: up to 24 months after randomization ]DOR in two arms based on RECIST V1.1 by IRRC and investigator.
- Time to progression (TTP) [ Time Frame: One assessment was performed every 6 weeks (±7 days) from the time of randomization, and once every 12 weeks (±7 days) after 48 weeks. ]TTP in two arms based on RECIST V1.1 by IRRC and investigator.
- Time to response (TTR) [ Time Frame: up to 24 months after randomization ]TTR in two arms based on RECIST V1.1 by IRRC and investigator.
- PFS [ Time Frame: up to 24 months after randomization ]PFS in two arms based on mRECIST by IRRC.
- Objective response rate (ORR) [ Time Frame: up to 24 months after randomization ]Objective response rate (ORR) in two arms based on mRECIST by IRRC.
- Time to progression (TTP) [ Time Frame: up to 24 months after randomization ]TTP in two arms based on mRECIST by IRRC.
- Duration of response (DOR) [ Time Frame: up to 24 months after randomization ]DOR in two arms based on mRECIST by IRRC.
- Disease control rate (DCR) [ Time Frame: up to 24 months after randomization ]DCR in two arms based on mRECIST by IRRC.
- Time to response (TTR) [ Time Frame: up to 24 months after randomization ]TTR in two arms based on mRECIST by IRRC.
- Anti-drug antibody (ADA) [ Time Frame: up to 24 months after randomization ]Immunogenicity measured by anti-drug antibody (ADA) for Sintilimab and IBI305.
- EORTC QLQ-C30 [ Time Frame: up to 24 months after randomization ]
- EORTC QLQ-HCC18 [ Time Frame: up to 24 months after randomization ]
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Hepatocellular carcinoma confirmed by histology/cytology. Cirrhosis meets the clinical diagnostic criteria for hepatocellular carcinoma of the American Association for the Diagnosis of Liver Diseases (AASLD).
- ECOG performance status between 0 and 1
- No systematic anti-tumor treatment has been performed.(End of postoperative adjuvant chemotherapy for more than 6 months allowed).
- Barcelona Clinic Liver Cancer stage C. BCLC stage B, not suitable for radical surgery and/or local treatment.
- At least 1 lesion with measurable disease at baseline by RECIST V1.1.
- Child-Pugh: <=7
- Adequate organ and bone marrow function.
Exclusion Criteria:
- With fibrous lamellar hepatocellular carcinoma, sarcomatoid hepatocellular carcinoma, cholangiocarcinoma components in tumor tissues.
- Have a history of hepatic encephalopathy or have a history of liver transplantation.
- With clinical symptoms requires drainage of pleural effusion, ascites or pericardial effusion.
- Central nervous system (CNS) metastasis.
- Uncontrolled high blood pressure, systolic blood pressure >140mmHg or diastolic blood pressure >90mmHg after optimal medical treatment.
- Local treatment for liver lesions within 4 weeks.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03794440
China, Shanghai | |
Hospital of Fudan University | |
Shanghai, Shanghai, China, 200032 |
Responsible Party: | Innovent Biologics (Suzhou) Co. Ltd. |
ClinicalTrials.gov Identifier: | NCT03794440 |
Other Study ID Numbers: |
CIBI338B301 |
First Posted: | January 7, 2019 Key Record Dates |
Last Update Posted: | January 22, 2021 |
Last Verified: | May 2020 |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
Carcinoma Carcinoma, Hepatocellular Neoplasms, Glandular and Epithelial Neoplasms by Histologic Type Neoplasms Adenocarcinoma Liver Neoplasms Digestive System Neoplasms |
Neoplasms by Site Digestive System Diseases Liver Diseases Sorafenib Antineoplastic Agents Protein Kinase Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action |